Last reviewed · How we verify
Remimazolam besylate and low-dose Esketamine
Remimazolam besylate and low-dose Esketamine is a Small molecule drug developed by Second Affiliated Hospital of Wenzhou Medical University. It is currently FDA-approved. Also known as: intravenous bolus remimazolam according to biased coin design.
At a glance
| Generic name | Remimazolam besylate and low-dose Esketamine |
|---|---|
| Also known as | intravenous bolus remimazolam according to biased coin design |
| Sponsor | Second Affiliated Hospital of Wenzhou Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remimazolam besylate and low-dose Esketamine CI brief — competitive landscape report
- Remimazolam besylate and low-dose Esketamine updates RSS · CI watch RSS
- Second Affiliated Hospital of Wenzhou Medical University portfolio CI
Frequently asked questions about Remimazolam besylate and low-dose Esketamine
What is Remimazolam besylate and low-dose Esketamine?
Remimazolam besylate and low-dose Esketamine is a Small molecule drug developed by Second Affiliated Hospital of Wenzhou Medical University.
Who makes Remimazolam besylate and low-dose Esketamine?
Remimazolam besylate and low-dose Esketamine is developed and marketed by Second Affiliated Hospital of Wenzhou Medical University (see full Second Affiliated Hospital of Wenzhou Medical University pipeline at /company/second-affiliated-hospital-of-wenzhou-medical-university).
Is Remimazolam besylate and low-dose Esketamine also known as anything else?
Remimazolam besylate and low-dose Esketamine is also known as intravenous bolus remimazolam according to biased coin design.
What development phase is Remimazolam besylate and low-dose Esketamine in?
Remimazolam besylate and low-dose Esketamine is FDA-approved (marketed).
Related
- Manufacturer: Second Affiliated Hospital of Wenzhou Medical University — full pipeline
- Also known as: intravenous bolus remimazolam according to biased coin design
- Compare: Remimazolam besylate and low-dose Esketamine vs similar drugs
- Pricing: Remimazolam besylate and low-dose Esketamine cost, discount & access